Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
ARA-290 vs LL-37
An educational, source-based comparison of ARA-290 and LL-37 — how each peptide works, what it's researched for, and what to know before going deeper.
Erythropoietin-derived peptide researched for neuropathy and tissue repair.
A synthetic 11-amino-acid peptide derived from the erythropoietin molecule. Research indicates it retains the tissue-protective (non-erythropoietic) effects of EPO via the β-common receptor, without stimulating red blood cell production.
- Small-fiber neuropathy and sarcoidosis
- Diabetic neuropathy
- Ischemia-reperfusion injury
- Autoimmune modulation
- • Investigational; not FDA-approved.
- • Does not raise hematocrit like full EPO molecule.
Human cathelicidin peptide with antimicrobial and immune-modulating activity.
The only human cathelicidin antimicrobial peptide. Research demonstrates broad antimicrobial activity against bacteria, viruses, and fungi, plus immunomodulatory effects on neutrophils, macrophages, and wound healing.
- Chronic biofilm infections
- Wound healing and dermatology
- Innate immune modulation
- • Not FDA-approved.
- • Pro-inflammatory effects possible at higher doses.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Two cited studies; independent replication needed.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| ARA-290 | ARA-290 in sarcoidosis-associated small-fiber neuropathy | Neurology | 2018 | Improved pain scores and corneal nerve fiber density in sarcoidosis patients. |
| ARA-290 | ARA-290 tissue protective effects | British Journal of Pharmacology | 2015 | Reviewed non-hematopoietic protective mechanisms via the innate repair receptor. |
| LL-37 | LL-37: a multifunctional host-defense peptide | Frontiers in Immunology | 2020 | Comprehensive review of antimicrobial and immunomodulatory roles. |
Side-effect & safety grid
- Investigational; not FDA-approved.
- Does not raise hematocrit like full EPO molecule.
- Not FDA-approved.
- Pro-inflammatory effects possible at higher doses.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
ARA-290 vs LL-37 — Key differences
- Class: ARA-290 is classified as Neuropathic · Immune Modulation, while LL-37 is Immune · Antimicrobial.
- Primary research focus: ARA-290 — small-fiber neuropathy and sarcoidosis; LL-37 — chronic biofilm infections.
- Tag: Neuropathic pain · Immune vs Immune · Antimicrobial.